BACKGROUND: Cardiac hypertrophy is associated with increased incidence of sudden death and susceptibility to proarrhythmic effects of antiarrhythmic agents. However, the in vivo electrophysiologic mechanism of the arrhythmias has not been investigated in detail. METHODS AND RESULTS: Dose-dependent susceptibility to Torsade de Pointes (TdP) by class III drug dofetilide, 3, 10, and 30 microg/kg, was compared in 6 control dogs (C) and in 5 dogs 6 to 8 weeks after induction of complete atrioventricular block (AVB) that resulted in ventricular hypertrophy (H). Tridimensional ventricular activation and repolarization (R) patterns were simultaneously analyzed from unipolar extracellular electrograms, and local R was measured from activation recovery intervals. Both R and transmural dispersion of R (TDR) were significantly greater in dogs with H compared with C. Dofetilide resulted in cycle length--dependent and dose-dependent prolongation of R, which was more marked in left ventricular endocardium/midmyocardium compared with epicardium, resulting in significant increase of TDR. These changes were more accentuated in dogs with H compared with C. All 5 dogs with H developed TdP at a dose of 3 to 10 microg/kg, whereas only 1 of 6 C dogs developed TdP at 30 microg/kg. TdP was initiated by subendocardial focal activity that infringed on TDR, resulting in functional conduction block and reentrant excitation. CONCLUSIONS: Enhanced susceptibility of hypertrophied heart to class III drugs is attributable to baseline increased TDR and greater dose-related accentuation of TDR compared with nonhypertrophied heart. This provides the electrophysiologic substrate for drug-induced TdP.
BACKGROUND:Cardiac hypertrophy is associated with increased incidence of sudden death and susceptibility to proarrhythmic effects of antiarrhythmic agents. However, the in vivo electrophysiologic mechanism of the arrhythmias has not been investigated in detail. METHODS AND RESULTS: Dose-dependent susceptibility to Torsade de Pointes (TdP) by class III drug dofetilide, 3, 10, and 30 microg/kg, was compared in 6 control dogs (C) and in 5 dogs 6 to 8 weeks after induction of complete atrioventricular block (AVB) that resulted in ventricular hypertrophy (H). Tridimensional ventricular activation and repolarization (R) patterns were simultaneously analyzed from unipolar extracellular electrograms, and local R was measured from activation recovery intervals. Both R and transmural dispersion of R (TDR) were significantly greater in dogs with H compared with C. Dofetilide resulted in cycle length--dependent and dose-dependent prolongation of R, which was more marked in left ventricular endocardium/midmyocardium compared with epicardium, resulting in significant increase of TDR. These changes were more accentuated in dogs with H compared with C. All 5 dogs with H developed TdP at a dose of 3 to 10 microg/kg, whereas only 1 of 6 C dogs developed TdP at 30 microg/kg. TdP was initiated by subendocardial focal activity that infringed on TDR, resulting in functional conduction block and reentrant excitation. CONCLUSIONS: Enhanced susceptibility of hypertrophied heart to class III drugs is attributable to baseline increased TDR and greater dose-related accentuation of TDR compared with nonhypertrophied heart. This provides the electrophysiologic substrate for drug-induced TdP.
Authors: Jurren M van Opstal; S Cora Verduyn; Stephan K G Winckels; Hendrik M Leerssen; Jet D M Leunissen; Hein J J Wellens; Marc A Vos Journal: J Interv Card Electrophysiol Date: 2002-06 Impact factor: 1.900
Authors: Enrique Lara-Pezzi; Philippe Menasché; Jean-Hugues Trouvin; Lina Badimón; John P A Ioannidis; Joseph C Wu; Joseph A Hill; Walter J Koch; Albert F De Felice; Peter de Waele; Valérie Steenwinckel; Roger J Hajjar; Andreas M Zeiher Journal: J Cardiovasc Transl Res Date: 2015-01-21 Impact factor: 4.132
Authors: Charles Antzelevitch; Luiz Belardinelli; Andrew C Zygmunt; Alexander Burashnikov; José M Di Diego; Jeffrey M Fish; Jonathan M Cordeiro; George Thomas Journal: Circulation Date: 2004-08-09 Impact factor: 29.690
Authors: Karan R Chadda; Ibrahim T Fazmin; Shiraz Ahmad; Haseeb Valli; Charlotte E Edling; Christopher L-H Huang; Kamalan Jeevaratnam Journal: Sleep Date: 2018-09-01 Impact factor: 5.849
Authors: Roy Chung; Penny L Houghtaling; Michael Tchou; Mark J Niebauer; Bruce D Lindsay; Patrick J Tchou; Mina K Chung Journal: Pacing Clin Electrophysiol Date: 2014-05-16 Impact factor: 1.976
Authors: Alexander Bauer; J Kevin Donahue; Frederik Voss; Ruediger Becker; Patricia Kraft; Julia C Senges; Kamilla Kelemen; Hugo A Katus; Wolfgang Schoels Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2004-02-19 Impact factor: 3.000